Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Barbara, Biedrzycki"'
Autor:
Mary E, Cooley, Barbara, Biedrzycki, Jeannine M, Brant, Marilyn J, Hammer, Robin M, Lally, Sharon, Tucker, Pamela K, Ginex
Publikováno v:
Cancer Nursing. 46:E110-E121
Adoption of evidence remains slow, leading to variations in practices and quality of care. Examining evidence-based interventions implemented within oncology settings can guide knowledge translation efforts.This integrative review aimed to (1) identi
Autor:
Hyam I. Levitsky, Kristen Hege, Richard Jones, Guang Haun Tu, Thomas C. Harding, Barbara Biedrzycki, Christina Chia, Lu Qin, Hua-Ling Tsai, Elizabeth Garrett-Mayer, Carole B. Miller, Kathleen Murphy, Christopher Gocke, Jeanne Kowalski, Yvette L. Kasamon, B. Douglas Smith
Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity. K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing vaccine derived from a CML cell line that expresses several CML-associated a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::259cce9075d95e9c8508b5e08dc816d5
https://doi.org/10.1158/1078-0432.c.6518467
https://doi.org/10.1158/1078-0432.c.6518467
Autor:
Hyam I. Levitsky, Kristen Hege, Richard Jones, Guang Haun Tu, Thomas C. Harding, Barbara Biedrzycki, Christina Chia, Lu Qin, Hua-Ling Tsai, Elizabeth Garrett-Mayer, Carole B. Miller, Kathleen Murphy, Christopher Gocke, Jeanne Kowalski, Yvette L. Kasamon, B. Douglas Smith
Supplementary Data from K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53ae04ff2945ed73b9f14b49f95b4e63
https://doi.org/10.1158/1078-0432.22441387.v1
https://doi.org/10.1158/1078-0432.22441387.v1
Publikováno v:
Methods in molecular medicine. 103
The management of patients with pancreatic cancer is a multidisciplinary approach that presents enormous challenges to the clinician. Overall 5-yr survival for all patients remains3%. Symptoms of early pancreas cancer are nonspecific. As such, only a
Autor:
Leisha A, Emens, Deborah, Armstrong, Barbara, Biedrzycki, Nancy, Davidson, Janice, Davis-Sproul, John, Fetting, Elizabeth, Jaffee, Beth, Onners, Steve, Piantadosi, Richard T, Reilly, Vered, Stearns, Irena, Tartakovsky, Kala, Visvanathan, Antonio, Wolff
Publikováno v:
Human gene therapy. 15(3)